Scholarlink

Introduction <p>To evaluate the long-term outcomes of half-dose half-dose photodynamic therapy (PDT) in the treatment of bullous variant central serous chorioretinopathy (bvCSC).</p> Methods <p>A retrospective single-center study of 18 patients, 31 eyes with bvCSC who received PDT between January 2012 and December 2021 with a minimum follow-up of 36&#xa0;months.</p> Results <p>During follow-up, a dry macula was achieved in all cases and no recurrence was witnessed. The mean number of PDT treatments was 1.2 sessions. Twenty-five (80.6%) eyes in 14 patients achieved complete fluid resolution after a single session. The earliest complete resolution of subretinal fluid occurred at 1&#xa0;month, while the latest was at 12&#xa0;months, with a mean time of 4.2&#xa0;months. The subretinal fibrinous exudates were completely resolved in all affected eyes, with the earliest resolution observed at 1&#xa0;month and the latest at 13&#xa0;month, with an average time of 5.9&#xa0;months. In seven (22.6%) eyes with pre-existing conditions, the subretinal fibrosis and scarring remained unchanged. The baseline average logMAR BCVA was 1.08 ± 0.55, and it improved to 0.74 ± 0.80 at final visit (<i>P</i> &lt; 0.001), with visual gain stabilizing at 24&#xa0;months. One eye (3.2%) with defects in the retinal pigmentary epithelium-choriocapillaris developed choroidal neovascularization 10&#xa0;months after treatment.</p> Conclusions <p>Our clinical data suggested half-dose PDT might offer a favorable safety and efficacy profile in treating conventional&#xa0;bvCSC, with visual gain stabilizing at 24&#xa0;months post-treatment. Cautious risk–benefit assessment remains essential for patients with high-risk ischemic anatomical features.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Half-Dose Photodynamic Therapy for Bullous Variant Central Serous Chorioretinopathy: A Long-Term Follow-Up

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月19日

查看全文
  • Yang Liu,
  • Chen Jiang,
  • Min Zhu,
  • Gezhi Xu,
  • Lei Li

摘要

Introduction

To evaluate the long-term outcomes of half-dose half-dose photodynamic therapy (PDT) in the treatment of bullous variant central serous chorioretinopathy (bvCSC).

Methods

A retrospective single-center study of 18 patients, 31 eyes with bvCSC who received PDT between January 2012 and December 2021 with a minimum follow-up of 36 months.

Results

During follow-up, a dry macula was achieved in all cases and no recurrence was witnessed. The mean number of PDT treatments was 1.2 sessions. Twenty-five (80.6%) eyes in 14 patients achieved complete fluid resolution after a single session. The earliest complete resolution of subretinal fluid occurred at 1 month, while the latest was at 12 months, with a mean time of 4.2 months. The subretinal fibrinous exudates were completely resolved in all affected eyes, with the earliest resolution observed at 1 month and the latest at 13 month, with an average time of 5.9 months. In seven (22.6%) eyes with pre-existing conditions, the subretinal fibrosis and scarring remained unchanged. The baseline average logMAR BCVA was 1.08 ± 0.55, and it improved to 0.74 ± 0.80 at final visit (P < 0.001), with visual gain stabilizing at 24 months. One eye (3.2%) with defects in the retinal pigmentary epithelium-choriocapillaris developed choroidal neovascularization 10 months after treatment.

Conclusions

Our clinical data suggested half-dose PDT might offer a favorable safety and efficacy profile in treating conventional bvCSC, with visual gain stabilizing at 24 months post-treatment. Cautious risk–benefit assessment remains essential for patients with high-risk ischemic anatomical features.